POLE and neoplasm: On the basis of the above studies, we further confirmed that POLE mutation EC is a tumor subtype with a high tumor mutational burden and good immunogenicity for molecular typing, which may be more effective for immunotherapy, by analyzing the database data and clinical sample data and combining them with immunohistochemical staining scores.